Self in vivo production of a synthetic biological drug CTLA4Ig using a minicircle vector

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Rim, Yeri Alice ^a   Yi, Hyoju ^a   Kim, Youngkyun ^a   Park, Narae ^a   Jung, Hyerin ^a   Kim, Juryun ^a   Jung, Seung Min ^a   Park, Sung Hwan ^a   Ju, Ji Hyeon ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; CIRCULAR DNA; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; IMMUNOSUPPRESSIVE AGENT;

ADMINISTRATION AND DOSAGE; ANIMAL; ARTHRITIS, EXPERIMENTAL; BIOSYNTHESIS; DBA MOUSE; DRUG EFFECTS; FEMALE; GENE EXPRESSION; GENE VECTOR; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOLOGY; REGULATORY T LYMPHOCYTE;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; DNA, CIRCULAR; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; GENETIC VECTORS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED DBA; MOLECULAR TARGETED THERAPY; T-LYMPHOCYTES, REGULATORY;

EID: 84923377338     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep06935     Document Type: Article

References (40)

1. Cutolo, M. &Nadler, S. G. Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmun Rev. 12, 758-767 (2013)
2. Vital, E. M. &Emery, P. Abatacept in the treatment of rheumatoid arthritis. Ther Clin Risk Manag. 2, 365-375 (2006)
3. Podojil, J. R. &Miller, S. D. Targeting the B7 family of co-stimulatory molecules: successes and challenges. BioDrugs. 27, 1-13 (2013)
4. McCoy, K. D.&LeGros, G. The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol. 77, 1-10 (1999)
5. Linsley, P. S. et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp Med. 174, 561-569 (1991)
6. Engelhardt, J. J., Sullivan, T. J. &Allison, J. P. CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J. Immunol. 177, 1052-1061 (2006)
7. Genovese, M. C. et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum. 63, 2854-2864 (2011)
8. Soini, E. J., Leussu, M. &Hallinen, T. Administration costs of intravenous biologic drugs for rheumatoid arthritis. Springerplus. 2, 531 (2013)
9. Chen, Z. Y., He, C. Y., Ehrhardt, A.&Kay,M.A.MinicircleDNAvectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther. 8, 495-500 (2003)
10. Gracey Maniar, L. E. et al. Minicircle DNA vectors achieve sustained expression reflected by active chromatin and transcriptional level. Mol Ther. 21, 131-138 (2013)
11. Kay, M. A., He, C. Y. &Chen, Z. Y. A robust system for production of minicircle DNA vectors. Nat Biotechnol. 28, 1287-1289
12. Gill, D. R., Pringle, I. A. &Hyde, S. C. Progress and prospects: the design and production of plasmid vectors. Gene Ther. 16, 165-171 (2009)
13. Huang, M. et al. Novel minicircle vector for gene therapy in murine myocardial infarction. Circulation. 120, S230-237 (2009)
14. Sebestyen, M. G. et al. Mechanism of plasmid delivery by hydrodynamic tail vein injection. I. Hepatocyte uptake of various molecules. J. Gene Med. 8, 852-873 (2006)
15. Andrianaivo, F., Lecocq, M., Wattiaux-De Coninck, S., Wattiaux, R. &Jadot, M. Hydrodynamics-based transfection of the liver: entrance into hepatocytes ofDNA that causes expression takes place very early after injection. J. Gene Med. 6, 877-883 (2004)
16. Budker, V. et al. Hypothesis: naked plasmid DNA is taken up by cells in vivo by a receptor-mediated process. J. Gene Med. 2, 76-88 (2000)
17. Kobayashi, N., Nishikawa, M., Hirata, K. &Takakura, Y. Hydrodynamics-based procedure involves transient hyperpermeability in the hepatic cellularmembrane: implication of a nonspecific process in efficient intracellular gene delivery. J. Gene Med. 6, 584-592 (2004)
18. Razmara, M., Hilliard, B., Ziarani, A. K., Chen, Y. H. &Tykocinski, M. L. CTLA-4 x Ig converts naive CD41CD25-T cells into CD41CD251regulatory T cells. Int. Immunol. 20, 471-483 (2008)
19. Ying, H. et al. Cutting edge: CTLA-4-B7 interaction suppresses Th17 cell differentiation. J. Immunol. 185, 1375-1378 (2010)
20. De Klerck, B. et al. Enhanced osteoclast development in collagen-induced arthritis in interferon-gamma receptor knock-out mice as related to increased splenic CD11b1 myelopoiesis. Arthritis Res Ther. 6, R220-231 (2004)
21. Alnaeeli, M., Penninger, J. M. &Teng, Y. T. Immune interactions with CD41 T cells promote the development of functional osteoclasts from murine CD11c1 dendritic cells. J. Immunol. 177, 3314-3326 (2006)
22. Zaiss, M. M. et al. Regulatory T cells protect from local and systemic bone destruction in arthritis. J. Immunol. 184, 7238-7246 (2010)
23. Axmann, R. et al. CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis. 67, 1603-1609 (2008)
24. Yue, D. et al. CTLA-4Ig blocks the development and progression of citrullinated fibrinogen-induced arthritis in DR4-transgenic mice. Arthritis Rheum. 62, 2941-2952 (2010)
25. Ijima, K. et al. Successful gene therapy via intraarticular injection of adenovirus vector containing CTLA4IgG in a murine model of type II collagen-induced arthritis. Hum Gene Ther. 12, 1063-1077 (2001)
26. Luo, G. et al. CTLA4Ig introduced by adenovirus vector locally to prolong the survival of xenogeneic skin grafts on rat burn wounds. J. Trauma. 59, 1209-1215 (2005)
27. Thummala, N. R. et al. A non-immunogenic adenoviral vector, coexpressing CTLA4Ig and bilirubin-uridine-diphosphoglucuronateglucuronosyltransferase permits long-term, repeatable transgene expression in the Gunn rat model of Crigler-Najjar syndrome. Gene Ther. 9, 981-990 (2002)
28. Marshall, E. Gene therapy death prompts review of adenovirus vector. Science 286, 2244-2245 (1999)
29. Yamamoto, M., Harigaya, T., Ichikawa, T., Hoshino, K. &Nakashima, K. Recombinant mouse prolactin: expression in Escherichia coli, purification and biological activity. J. Mol Endocrinol. 8, 165-172 (1992)
30. Knoerzer, D. B., Karr, R. W., Schwartz, B. D. &Mengle-Gaw, L. J. Collageninduced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J. Clin Invest. 96, 987-993 (1995)
31. Shedlock, D. J. &Weiner, D. B. DNA vaccination: antigen presentation and the induction of immunity. J. Leukoc Biol. 68, 793-806 (2000)
32. Hassett, D. E., Slifka, M. K., Zhang, J. &Whitton, J. L. Direct ex vivo kinetic and phenotypic analyses of CD8(1) T-cell responses induced by DNA immunization. J. Virol. 74, 8286-8291 (2000)
33. Hassett, D. E., Zhang, J., Slifka, M. &Whitton, J. L. Immune responses following neonatal DNA vaccination are long-lived, abundant, and qualitatively similar to those induced by conventional immunization. J. Virol. 74, 2620-2627 (2000)
34. Osborn, M. J. et al. Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of alpha-L-iduronidase in mice with mucopolysaccharidosis type I. Mol Ther. 19, 450-460 (2011)
35. Chen, Z. Y., Riu, E.,He, C. Y., Xu, H. &Kay, M. A. Silencing of episomal transgene expression in liver by plasmid bacterial backbone DNA is independent of CpG methylation. Mol Ther. 16, 548-556 (2008)
36. Chen, Z. Y., He, C. Y., Meuse, L. &Kay, M. A. Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo. Gene Ther. 11, 856-864 (2004)
37. Ebina, K. et al. Adenovirus-mediated gene transfer of adiponectin reduces the severity of collagen-induced arthritis in mice. Biochem Biophys Res Commun. 378, 186-191 (2009)
38. Tepper, M. A., Linsley, P. S., Tritschler, D. &Esselstyn, J. M. Tolerance induction by soluble CTLA4 in a mouse skin transplant model. Transplant Proc. 26, 3151-3154 (1994)
39. Haggerty, H. G., Bigbee, C., Gonchoroff, D. G. &Flynn, J. L. Abatacept treatment does not impair host resistance to chronic mycobacterium tuberculosis infection in mice. Ann Rheum Dis. 65, 319-319 (2006)
40. Huckel, M. et al. Attenuation of murine antigen-induced arthritis by treatment with a decoy oligodeoxynucleotide inhibiting signal transducer and activator of transcription-1 (STAT-1). Arthritis Res Ther. 8, R17 (2006)